NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis $6.66 -0.04 (-0.60%) Closing price 08/1/2025 03:56 PM EasternExtended Trading$6.66 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Quoin Pharmaceuticals Stock (NASDAQ:QNRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Quoin Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.67▼$6.8250-Day Range$6.66▼$9.8652-Week Range$5.01▼$54.95Volume3,184 shsAverage Volume4,032 shsMarket Capitalization$3.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Read More Quoin Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreQNRX MarketRank™: Quoin Pharmaceuticals scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Quoin Pharmaceuticals. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Quoin Pharmaceuticals are expected to grow in the coming year, from ($2.05) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Quoin Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.56% of the outstanding shares of Quoin Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently decreased by 8.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.56% of the outstanding shares of Quoin Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently decreased by 8.00%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.37 News SentimentQuoin Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Quoin Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for QNRX on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.46% of the stock of Quoin Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address QNRX Stock News HeadlinesQuoin Pharmaceuticals (QNRX) to Release Quarterly Earnings on Thursday2 hours ago | americanbankingnews.comQuoin Pharmaceuticals stock rises after positive clinical updatesJuly 31 at 3:14 AM | investing.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | finanznachrichten.deQuoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | globenewswire.comQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - MorningstarJune 27, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - NasdaqJune 27, 2025 | nasdaq.comQNRX - Quoin Pharmaceuticals Ltd ADR Executives - MorningstarJune 26, 2025 | morningstar.comMSee More Headlines QNRX Stock Analysis - Frequently Asked Questions How have QNRX shares performed this year? Quoin Pharmaceuticals' stock was trading at $22.7745 on January 1st, 2025. Since then, QNRX stock has decreased by 70.8% and is now trading at $6.66. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($6.50) EPS for the quarter, missing analysts' consensus estimates of ($3.85) by $2.65. When did Quoin Pharmaceuticals' stock split? Shares of Quoin Pharmaceuticals reverse split on Monday, July 17th 2023.The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quoin Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings5/13/2025Today8/02/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:QNRX CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($48.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-148.97% Return on Assets-77.23% Debt Debt-to-Equity RatioN/A Current Ratio2.57 Quick Ratio2.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$35.47 per share Price / Book0.19Miscellaneous Outstanding Shares590,000Free Float509,000Market Cap$3.93 million OptionableNot Optionable Beta1.44 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:QNRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.